FBIO Stock Forecast 2025-2026
Distance to FBIO Price Targets
FBIO Price Momentum
🤔 Considering Fortress Biotech (FBIO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest FBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, FBIO has a bullish consensus with a median price target of $16.00 (ranging from $4.00 to $26.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $1.67, the median forecast implies a 858.1% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 1,456.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FBIO Analyst Ratings
FBIO Price Target Range
Latest FBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2025 | Roth MKM | Jason Wittes | Buy | Reiterates | $16.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $26.00 |
| Jul 19, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $24.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $0.00 |
| May 16, 2024 | Roth MKM | Jason Wittes | Buy | Reiterates | $10.00 |
| Mar 19, 2024 | Alliance Global Partners | Buy | Initiates | $5.00 | |
| Mar 15, 2024 | Roth MKM | Jason Wittes | Buy | Reinstates | $10.00 |
| Nov 29, 2023 | Roth MKM | Scott Henry | Buy | Maintains | $15.00 |
| Aug 15, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $5.00 |
| May 16, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Maintains | $5.00 |
| Apr 6, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $5.00 |
| Aug 4, 2022 | Ladenburg Thalmann | Jeffrey Cohen | Buy | Initiates | $6.00 |
| Jul 14, 2022 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $6.00 |
| Apr 20, 2021 | Roth Capital | Buy | Maintains | $5.00 | |
| Oct 13, 2020 | Roth Capital | Buy | Maintains | $4.75 | |
| Oct 12, 2020 | HC Wainwright & Co. | Buy | Maintains | $10.00 | |
| Oct 2, 2020 | Benchmark | Buy | Initiates | $0.00 | |
| Mar 13, 2020 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $6.00 |
| Mar 13, 2020 | B. Riley FBR | Buy | Maintains | $0.00 | |
| Feb 13, 2020 | Cantor Fitzgerald | Overweight | Initiates | $0.00 |
Fortress Biotech Inc. (FBIO) Competitors
The following stocks are similar to Fortress Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fortress Biotech Inc. (FBIO) Financial Data
Fortress Biotech Inc. has a market capitalization of $45.69M with a P/E ratio of -0.2x. The company generates $81.50M in trailing twelve-month revenue with a -59.5% profit margin.
Revenue growth is -7.1% quarter-over-quarter, while maintaining an operating margin of -151.0% and return on equity of -4,327.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Fortress Biotech Inc. (FBIO) Business Model
About Fortress Biotech Inc.
Develops and commercializes biopharmaceutical products.
The company operates by acquiring and developing therapies through subsidiaries and licensing agreements. This innovative partnership model allows for specialized focus on early-stage drug candidates, enabling the company to progress its portfolio of treatments for rare diseases, cancer, and other serious health conditions.
Fortress Biotech aims to address unmet medical needs and foster advancements in healthcare by bringing breakthrough therapies to market, significantly impacting the pharmaceutical innovation landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
186
CEO
Dr. Lindsay Allan Rosenwald
Country
United States
IPO Year
2011
Website
www.fortressbiotech.comFortress Biotech Inc. (FBIO) Latest News & Analysis
Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics (CKPT) to Sun Pharmaceutical, citing concerns over conflicts with controlling shareholder Fortress Biotech (FBIO).
Concerns over potential conflicts of interest in Checkpoint's sale to Sun Pharmaceutical could affect shareholder value and impact investor sentiment regarding the deal's fairness.
Journey Medical Corporation (Nasdaq: DERM) will participate in the 37th Annual ROTH Conference from March 16-18, 2025, focusing on FDA-approved dermatological products.
Journey Medical's participation in the ROTH Conference may enhance visibility, attract investor interest, and influence stock performance through potential partnerships or funding opportunities.
Sun Pharma will acquire Checkpoint Therapeutics for $4.10 per share, totaling up to $355 million, plus contingent rights. The deal aims to enhance their oncology portfolio with UNLOXCYT™.
Sun Pharma's acquisition of Checkpoint enhances its oncology portfolio with UNLOXCYT™, potentially increasing revenue and market share in a growing cancer treatment sector.
The U.S. FDA approved Emrosi™ (Minocycline Hydrochloride 40 mg) for treating inflammatory lesions of rosacea in adults, effective November 2024.
The FDA approval of Emrosi™ signals potential revenue growth for the drug's manufacturer, positively impacting stock value and market confidence in their pipeline.
DFD-29, a minocycline hydrochloride capsule, met all primary and secondary endpoints in a 16-week trial with no significant safety concerns.
Successful trial results for DFD-29 indicate potential market approval and revenue generation, positively impacting the company's stock value and investor confidence.
Mustang Bio, Inc. (Nasdaq: MBIO) has regained compliance with Nasdaq's minimum stockholders' equity requirement, as confirmed by Nasdaq.
Mustang Bio's regained compliance with Nasdaq's equity requirement enhances its stability, potentially increasing investor confidence and attracting more institutional investment.
Frequently Asked Questions About FBIO Stock
What is Fortress Biotech Inc.'s (FBIO) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Fortress Biotech Inc. (FBIO) has a median price target of $16.00. The highest price target is $26.00 and the lowest is $4.00.
Is FBIO stock a good investment in 2025?
According to current analyst ratings, FBIO has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FBIO stock?
Wall Street analysts predict FBIO stock could reach $16.00 in the next 12 months. This represents a 858.1% increase from the current price of $1.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fortress Biotech Inc.'s business model?
The company operates by acquiring and developing therapies through subsidiaries and licensing agreements. This innovative partnership model allows for specialized focus on early-stage drug candidates, enabling the company to progress its portfolio of treatments for rare diseases, cancer, and other serious health conditions.
What is the highest forecasted price for FBIO Fortress Biotech Inc.?
The highest price target for FBIO is $26.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 1,456.9% increase from the current price of $1.67.
What is the lowest forecasted price for FBIO Fortress Biotech Inc.?
The lowest price target for FBIO is $4.00 from at , which represents a 139.5% increase from the current price of $1.67.
What is the overall FBIO consensus from analysts for Fortress Biotech Inc.?
The overall analyst consensus for FBIO is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are FBIO stock price projections?
Stock price projections, including those for Fortress Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
